HES history
HES was introduced in clinical practice in the 1960s, since then concerns on its safety and efficacy have been consistently and extensively raised (1-3). (5) . These evidence were further confirmed in 1981 when was reported: "Following massive infusions,(...) a wide variety of laboratory abnormalities were observed, and hemorrhage was documented(…)" (6) . In 2002 the Blood Products Advisory Committee, recommended the Food and Drug Administration (FDA) to change the labeling of a 6% HES product because of the increased risk of bleeding during cardiopulmonary bypass in patients whose coagulation status is already impaired; this request was approved by the FDA in 2003 that added a warning statement (7).
As early as in 1968, it was reported abnormal massive bleeding in patients that received HES and Authors commented: "(…)there is need for further investigation (…)in patients being transfused with this substance" (4). In 1975, Alexander B and coll reported: "(…)the hemostatic defect associated with the use of (HES-like) plasma substitutes is a form of induced von Willebrand-disease or disseminated intravascular clotting, ensuing from precipitation and removal of v. W. factor(s), Factors VIII and I, microcirculatory abnormality, and platelet malfunction"
Additional concerns, related to renal damage, were reported since 1991 when was found: "(…)acute deterioration of an already existing nephropathy" with development of transient renal failure in patients underwent to hemorheological therapy through hemodilution (8) . These evidence were further confirmed in 1993 when renal histological lesions on transplanted kidneys associated with HES use were described (9, 10 Of interest, since 2010, Joachim Boldt -a German anesthesiologist and worldwide known scientist, an "eminence" in fluid therapy and a strong supporter of HES-was accused of forgery and falsification of study data, indicted into a penal trial, stripped of his professorship and he is currently under criminal investigation (14) . After that, >90 studies related to HES have been withdrawn by international anesthesia and critical care journals (15) . His case has been included among the biggest medical research scandal and his fraudulent studies caused significant harm to critically ill patients (16) . In 2013, a meta-analysis on HES use in ICU patients-that excluded data from Boldt's studies-showed an increase risk of acute kidney injury and higher mortality (17 (29) . Furthermore, the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI) and the national societies of Iceland, Denmark, Finland, Sweden and Norway, published a letter where they fully support the recommendation to suspend the market authorisation of HES solutions in the name of the guiding principle of primum non nocere (first do no harm) (30) .
It is now time for Nemesis ("The Ineludible"….justice brought by the time) to come for the appropriate retribution against those who succumbed to hubris (the excess of self confidence that -according Aristotle definition-turns into: "shaming the victim"). 
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